3D Mesenchymal Stem Cell Spheroids for Detrusor Underactivity

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current treatments for detrusor underactivity, such as pharmacological therapy, physical therapy, and invasive surgical interventions, are limited in efficacy and safety, and conventional two-dimensional cell culture methods fail to mimic the in vivo microenvironment, leading to suboptimal cellular function and low transplantation efficiency.

Innovation Solution

A cell preparation comprising three-dimensional cell aggregates formed by seeding mesenchymal stem cells in culture wells with low-protein-adhesion coating, cultured at specific densities and durations, to promote intercellular interactions and gene expression, enhancing bladder muscle contractility.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of manufacture

If conventional two-dimensional cell culture is used, then the culture method is simple and widely used, but it fails to mimic the in vivo three-dimensional microenvironment, resulting in suboptimal cellular function and reduced therapeutic efficacy

Engineering Contradiction:
Improvesimplicity of cell culture methodVSAvoidcellular function and therapeutic efficacy
Core Design Contradiction:
Ease of manufactureVSReliability

Solution Approach 1:

The patent transitions from conventional two-dimensional cell culture to three-dimensional cell aggregate culture. Cells are cultured in suspension forming spherical aggregates, which mimics the in vivo microenvironment more closely. This dimensional change enables better intercellular signaling, tissue architecture formation, and cellular function while maintaining culture simplicity through standardized protocols.

Inventive Principle:
Principle #17Another dimension (Dimensionality change)

2Ease of operation

If two-dimensional cell culture is used, then the culture process is straightforward, but intercellular signaling and tissue architecture formation are restricted

Engineering Contradiction:
Improveease of cell culture processVSAvoidintercellular signaling and tissue architecture formation
Core Design Contradiction:
Ease of operationVSAdaptability or versatility

Solution Approach 1:

The invention implements three-dimensional cell aggregate culture where cells are grown in suspension rather than on a surface. This spatial reconfiguration enables complex intercellular signaling networks and proper tissue architecture formation while keeping the culture process operationally simple through standardized suspension culture protocols.

Inventive Principle:
Principle #17Another dimension (Dimensionality change)

Solution Approach 2:

The patent changes critical culture parameters including cell density, culture medium composition, and incubation conditions to optimize three-dimensional aggregate formation. These parameter adjustments facilitate enhanced intercellular communication and tissue-like structure development while maintaining ease of operation.

Inventive Principle:
Principle #35Parameter changes

3Ease of manufacture

If conventional cell culture methods are used, then the preparation process is simple, but post-transplantation cell survival is reduced

Engineering Contradiction:
Improvesimplicity of cell preparationVSAvoidpost-transplantation cell survival
Core Design Contradiction:
Ease of manufactureVSReliability

Solution Approach 1:

The patent employs three-dimensional cell aggregate culture instead of conventional two-dimensional monolayer culture. This dimensional change preserves cell membrane integrity and reduces mechanical damage during handling, thereby improving post-transplantation cell survival while keeping the preparation process simple through standardized protocols.

Inventive Principle:
Principle #17Another dimension (Dimensionality change)

Solution Approach 2:

The three-dimensional aggregate structure provides a protective microenvironment for cells before transplantation. The aggregate architecture cushions cells against mechanical stress and facilitates better survival rates upon implantation, while the overall preparation process remains straightforward.

Inventive Principle:
Principle #11Beforehand cushioning (Prior cushioning)

4Ease of operation

If pharmacological therapy is used to stimulate bladder contraction, then symptom relief is achieved, but side effects occur and tissue repair is not possible

Engineering Contradiction:
Improveease of symptom reliefVSAvoidside effects and lack of tissue repair
Core Design Contradiction:
Ease of operationVSObject-affected harmful factors

Solution Approach 1:

The patent uses autologous mesenchymal stem cells that can self-differentiate into bladder smooth muscle cells and other relevant cell types. This self-service capability enables both symptom relief through functional stimulation and tissue repair through regeneration, eliminating the need for external pharmacological agents that cause side effects.

Inventive Principle:
Principle #25Self-service

Solution Approach 2:

The invention changes the treatment approach from pharmacological parameter adjustment to cellular parameter modification. By altering cell morphology, gene expression, and functional properties through three-dimensional culture, the therapy achieves both symptom relief and tissue repair without pharmacological side effects.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The cell preparation effectively restores bladder muscle contractile function, improves gene expression, and enhances cell survival and therapeutic efficacy by mimicking the in vivo microenvironment and promoting tissue repair.

Implementation Method 1

each of the culture wells comprises a low-protein-adhesion coating

Methodology Applied
Scientific EffectProtein adsorption: Adsorption

Implementation Method 2

the cell aggregate comprises a plurality of target cells, and each cell aggregate comprises 30 to 600 of the target cells

Methodology Applied
Scientific EffectCell differentiation:

Data Source

PatentEP4667010A1Cell composition for use in the treatment of detrusor underactivity and method for preparing the same
Publication Date: 2025.12.24 METATECH (AP) INC
  • EP4667010A1 patent drawingFigure 1
  • EP4667010A1 patent drawingFigure 2
  • EP4667010A1 patent drawingFigure 3

AI summary

The present invention provides a cell composition for use in the treatment of detrusor underactivity and a method for preparing the same. The cell composition comprises a cell spheroid formed by seeding a plurality of mesenchymal stem cells in a culture device comprising a plurality of culture wells, wherein each of the culture wells has a surface coated with a low-protein-adhesion layer, and culturing the cells under the conditions to induce spheroid formation. Through the cell composition of the present invention, three-dimensional structured cell spheroids are formed to promote intercellular interactions and physiological function expression, thereby enhancing cell survival rates and functional performance after transplantation. In particular, the cell composition effectively facilitates the repair and restoration of contractile function of bladder muscle tissue, thereby improving the clinical symptoms associated with detrusor underactivity.